Molecular mechanisms underlying levodopa‐induced dyskinesia
Identifieur interne : 002763 ( Main/Exploration ); précédent : 002762; suivant : 002764Molecular mechanisms underlying levodopa‐induced dyskinesia
Auteurs : Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Veronica Ghiglieri [Italie] ; Barbara Picconi [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Dopamine and cAMP-Regulated Phosphoprotein 32 (drug effects), Dopamine and cAMP-Regulated Phosphoprotein 32 (physiology), Dyskinesia, Humans, Levodopa, Levodopa (adverse effects), L‐dopa, Movement Disorders (etiology), Nervous system diseases, Neuronal Plasticity (drug effects), Neuronal Plasticity (physiology), Parkinson disease, Parkinson's disease, Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (physiology), Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (physiology), Synaptic plasticity, dyskinesia, synaptic plasticity.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , drug effects : Dopamine and cAMP-Regulated Phosphoprotein 32, Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , physiology : Dopamine and cAMP-Regulated Phosphoprotein 32, Receptors, Dopamine D1, Receptors, Dopamine D2.
- drug effects : Neuronal Plasticity.
- etiology : Movement Disorders.
- physiology : Neuronal Plasticity.
- Humans.
Abstract
Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease, chronic therapy with this pharmacological compound initiates a complex cascade of cellular and molecular downstream effects resulting in the development of abnormal involuntary movements. The precise mechanisms underlying the development of levodopa induced dyskinesia, however, are far from being completely elucidated. In the present review, we will describe changes in long‐term synaptic excitability following dopamine (DA) denervation and long‐term levodopa treatment leading to abnormal involuntary movements. In particular, we will address the role of both DA D1 receptors and NMDA glutamate receptors in the induction and maintenance of dyskinesia and abnormal synaptic plasticity. We will also describe the possible interaction between these two receptors in the pathophysiology of dyskinesia taking the advantage of the existing knowledge concerning the mechanisms underlying drug abuse. This latter pathophysiological condition, in fact, seems to share several biochemical transduction pathways with those implicated in levodopa‐induced dyskinesia. Finally, we will briefly discuss the possible implication of A2A adenosine receptors in long‐term motor complications of levodopa therapy and focus on the interaction between A2A and D2 receptors. Future studies are required to understand how the interaction between these various biochemical steps converge to produce a long‐term change in neuronal excitability within the basal ganglia leading to abnormal involuntary movements following levodopa treatment in the DA‐denervated state. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22019
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000332
- to stream Istex, to step Curation: 000332
- to stream Istex, to step Checkpoint: 001319
- to stream PubMed, to step Corpus: 002056
- to stream PubMed, to step Curation: 002056
- to stream PubMed, to step Checkpoint: 002214
- to stream Ncbi, to step Merge: 002307
- to stream Ncbi, to step Curation: 002307
- to stream Ncbi, to step Checkpoint: 002307
- to stream Main, to step Merge: 003341
- to stream PascalFrancis, to step Corpus: 001134
- to stream PascalFrancis, to step Curation: 001B85
- to stream PascalFrancis, to step Checkpoint: 001190
- to stream Main, to step Merge: 003798
- to stream Main, to step Curation: 002763
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular mechanisms underlying levodopa‐induced dyskinesia</title>
<author><name sortKey="Calabresi, Paolo" sort="Calabresi, Paolo" uniqKey="Calabresi P" first="Paolo" last="Calabresi">Paolo Calabresi</name>
</author>
<author><name sortKey="Di Filippo, Massimiliano" sort="Di Filippo, Massimiliano" uniqKey="Di Filippo M" first="Massimiliano" last="Di Filippo">Massimiliano Di Filippo</name>
</author>
<author><name sortKey="Ghiglieri, Veronica" sort="Ghiglieri, Veronica" uniqKey="Ghiglieri V" first="Veronica" last="Ghiglieri">Veronica Ghiglieri</name>
</author>
<author><name sortKey="Picconi, Barbara" sort="Picconi, Barbara" uniqKey="Picconi B" first="Barbara" last="Picconi">Barbara Picconi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CECD3BD602E3EF08DE4FC10AFFFC472FFD82FDBA</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22019</idno>
<idno type="url">https://api.istex.fr/document/CECD3BD602E3EF08DE4FC10AFFFC472FFD82FDBA/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000332</idno>
<idno type="wicri:Area/Istex/Curation">000332</idno>
<idno type="wicri:Area/Istex/Checkpoint">001319</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Calabresi P:molecular:mechanisms:underlying</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18781674</idno>
<idno type="wicri:Area/PubMed/Corpus">002056</idno>
<idno type="wicri:Area/PubMed/Curation">002056</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002214</idno>
<idno type="wicri:Area/Ncbi/Merge">002307</idno>
<idno type="wicri:Area/Ncbi/Curation">002307</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002307</idno>
<idno type="wicri:Area/Main/Merge">003341</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0466147</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001134</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B85</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001190</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Calabresi P:molecular:mechanisms:underlying</idno>
<idno type="wicri:Area/Main/Merge">003798</idno>
<idno type="wicri:Area/Main/Curation">002763</idno>
<idno type="wicri:Area/Main/Exploration">002763</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Molecular mechanisms underlying levodopa‐induced dyskinesia</title>
<author><name sortKey="Calabresi, Paolo" sort="Calabresi, Paolo" uniqKey="Calabresi P" first="Paolo" last="Calabresi">Paolo Calabresi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia</wicri:regionArea>
<wicri:noRegion>Perugia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Fondazione Santa Lucia, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Di Filippo, Massimiliano" sort="Di Filippo, Massimiliano" uniqKey="Di Filippo M" first="Massimiliano" last="Di Filippo">Massimiliano Di Filippo</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia</wicri:regionArea>
<wicri:noRegion>Perugia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Fondazione Santa Lucia, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ghiglieri, Veronica" sort="Ghiglieri, Veronica" uniqKey="Ghiglieri V" first="Veronica" last="Ghiglieri">Veronica Ghiglieri</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Fondazione Santa Lucia, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Picconi, Barbara" sort="Picconi, Barbara" uniqKey="Picconi B" first="Barbara" last="Picconi">Barbara Picconi</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Fondazione Santa Lucia, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008">2008</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="supplement">S3</biblScope>
<biblScope unit="page" from="S570">S570</biblScope>
<biblScope unit="page" to="S579">S579</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CECD3BD602E3EF08DE4FC10AFFFC472FFD82FDBA</idno>
<idno type="DOI">10.1002/mds.22019</idno>
<idno type="ArticleID">MDS22019</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Dopamine and cAMP-Regulated Phosphoprotein 32 (drug effects)</term>
<term>Dopamine and cAMP-Regulated Phosphoprotein 32 (physiology)</term>
<term>Dyskinesia</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>L‐dopa</term>
<term>Movement Disorders (etiology)</term>
<term>Nervous system diseases</term>
<term>Neuronal Plasticity (drug effects)</term>
<term>Neuronal Plasticity (physiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Receptors, Dopamine D1 (drug effects)</term>
<term>Receptors, Dopamine D1 (physiology)</term>
<term>Receptors, Dopamine D2 (drug effects)</term>
<term>Receptors, Dopamine D2 (physiology)</term>
<term>Synaptic plasticity</term>
<term>dyskinesia</term>
<term>synaptic plasticity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Dopamine and cAMP-Regulated Phosphoprotein 32</term>
<term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Dopamine and cAMP-Regulated Phosphoprotein 32</term>
<term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neuronal Plasticity</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neuronal Plasticity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Plasticité synaptique</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease, chronic therapy with this pharmacological compound initiates a complex cascade of cellular and molecular downstream effects resulting in the development of abnormal involuntary movements. The precise mechanisms underlying the development of levodopa induced dyskinesia, however, are far from being completely elucidated. In the present review, we will describe changes in long‐term synaptic excitability following dopamine (DA) denervation and long‐term levodopa treatment leading to abnormal involuntary movements. In particular, we will address the role of both DA D1 receptors and NMDA glutamate receptors in the induction and maintenance of dyskinesia and abnormal synaptic plasticity. We will also describe the possible interaction between these two receptors in the pathophysiology of dyskinesia taking the advantage of the existing knowledge concerning the mechanisms underlying drug abuse. This latter pathophysiological condition, in fact, seems to share several biochemical transduction pathways with those implicated in levodopa‐induced dyskinesia. Finally, we will briefly discuss the possible implication of A2A adenosine receptors in long‐term motor complications of levodopa therapy and focus on the interaction between A2A and D2 receptors. Future studies are required to understand how the interaction between these various biochemical steps converge to produce a long‐term change in neuronal excitability within the basal ganglia leading to abnormal involuntary movements following levodopa treatment in the DA‐denervated state. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
<region><li>Latium</li>
</region>
<settlement><li>Rome</li>
</settlement>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Calabresi, Paolo" sort="Calabresi, Paolo" uniqKey="Calabresi P" first="Paolo" last="Calabresi">Paolo Calabresi</name>
</noRegion>
<name sortKey="Calabresi, Paolo" sort="Calabresi, Paolo" uniqKey="Calabresi P" first="Paolo" last="Calabresi">Paolo Calabresi</name>
<name sortKey="Di Filippo, Massimiliano" sort="Di Filippo, Massimiliano" uniqKey="Di Filippo M" first="Massimiliano" last="Di Filippo">Massimiliano Di Filippo</name>
<name sortKey="Di Filippo, Massimiliano" sort="Di Filippo, Massimiliano" uniqKey="Di Filippo M" first="Massimiliano" last="Di Filippo">Massimiliano Di Filippo</name>
<name sortKey="Ghiglieri, Veronica" sort="Ghiglieri, Veronica" uniqKey="Ghiglieri V" first="Veronica" last="Ghiglieri">Veronica Ghiglieri</name>
<name sortKey="Picconi, Barbara" sort="Picconi, Barbara" uniqKey="Picconi B" first="Barbara" last="Picconi">Barbara Picconi</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002763 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002763 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:CECD3BD602E3EF08DE4FC10AFFFC472FFD82FDBA |texte= Molecular mechanisms underlying levodopa‐induced dyskinesia }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |